GlassScriptPhysician profile
Kyle Gennaro
NPI 1477087187
$5,213.82
in general payments reported to CMS, 2019-2025
28 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.48 · 2022: $1,340 · 2023: $987 · 2024: $1,099 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681 · Education: $136 · Entertainment: $41.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.68 |
| Education | $136.00 |
| Entertainment | $41.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,164.29 | 2022-2024 | Lithovue, Rezum Generator, Ams 700 Cxr Rte Kit |
| Sumitomo Pharma America, INC. | $713.37 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $673.06 | 2022-2025 | Myrbetriq, Xtandi |
| Ferring Pharmaceuticals INC. | $388.60 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $312.65 | 2020-2025 | |
| Antares Pharma, INC. | $299.39 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $284.58 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $211.65 | 2022-2024 | Xiaflex |
| Endo USA, INC. | $174.89 | 2024-2025 | Xiaflex |
| Urogen Pharma, INC. | $126.55 | 2023-2025 | Jelmyto |
| Medtronic, INC. | $107.23 | 2022-2025 | Interstim |
| Immunitybio, INC. | $93.96 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.07 | 2024 | |
| Olympus America INC. | $74.61 | 2023-2025 | Itind System, Olympus, Bovie |
| Myriad Genetic Laboratories, INC. | $65.95 | 2023-2024 | Prolaris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $54.82 | 2025 | |
| Telix Pharmaceuticals | $54.20 | 2024-2025 | Illuccix |
| Halozyme INC | $49.74 | 2023 | |
| Coloplast Corp | $47.92 | 2025 | |
| Edap Technomed INC | $41.75 | 2025 | |
| Mission Pharmacal Company | $37.88 | 2022-2023 | Uribel |
| Janssen Biotech, INC. | $30.13 | 2024 | Erleada |
| Verity Pharmaceuticals INC. | $29.17 | 2023 | Trelstar |
| Conmed Corporation | $22.54 | 2023 | Airseal |
| Kowa Pharmaceuticals America, INC. | $19.32 | 2022 | |
| Axonics, INC. | $18.98 | 2024 | Axonics |
| Progenics Pharmaceuticals, INC. | $17.62 | 2023 | Pylarify |
| Novo Nordisk INC | $15.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Gennaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.